SBIR Phase I: Novel Connexin-Based Peptide for the Treatment of Age-Related Macular Degeneration

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1215149
Agency Tracking Number: 1215149
Amount: $148,803.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solicitation Year: 2012
Solicitation Topic Code: BC
Solicitation Number: N/A
Small Business Information
475-A East Bay Street, Charleston, SC, 29403-6656
DUNS: 602545654
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Gautam Ghatnekar
 (843) 860-8785
Business Contact
 Gautam Ghatnekar
Phone: (843) 860-8785
Research Institution
This Small Business Innovation Research (SBIR) Phase I project is a feasibility assessment of the ocular delivery of a synthetic peptide, ACT1, for the treatment of Age-Related Macular Degeneration (AMD). AMD is a retinal disease in patients who progressively lose their central vision through pathological and damaging conditions of the macula primarily by the development of leaky blood vessels in the retina of the eye. The objective is to determine whether ACT1 can be transported passively to the retinal epithelial cell layer, elicit a response consistently on blood vessel lesions of the macula, and slow the progression or restore visual functions in vivo as a milestone for the further development of a topical eye drop formulation. The broader/commercial impacts of this research are manifold and foremost the potential commercialization of a much needed treatment option for patients suffering from AMD. AMD affects approximately 25 to 30 million people worldwide and is the leading cause of vision loss for Americans 60 years old or older, with close to 2 million people suffering in the United States. Current treatments of AMD require the use of drugs are administered chronically to patients by injections into the eyes that can be quite painful as well as eliciting further safety concerns, and are modestly effective in slowing the rate of vision loss. A topically delivered therapeutic may provide a variety of benefits including easier, faster, and cheaper treatments of patients, patient self-care, and potentially jumpstart a new industry for the optometric management of AMD.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government